Compositions and methods for treating endometriosis
Provided herein are methods of treating and/or preventing endometriosis or symptom thereof, assays for diagnosing/prognosing endometriosis, compositions and formulations for treating and/or preventing endometriosis or symptom thereof, and populations of endometiotic cells, including life-extended populations of cells.
1. A method of treating endometriosis in a subject in need thereof comprising:
administering an autophagic inhibitor to the subject in an amount effective to treat endometriosis in the subject.
2. The method of claim 1 , wherein the autophagic inhibitor is selected from the group consisting of chloriquine, Lys05, hydroxychloriquine, pharmaceutically acceptable salts thereof, ATG5 siRNA, ATG7 siRNA, or combinations thereof.
3. The method of claim 1 , wherein the autophagic inhibitor is hydroxychloriquine.
4. The method of claim 1 , wherein the effective amount ranges from about 1 mg/kg to about 200 mg/kg.
5. The method of claim 1 , wherein the effective amount is administered in a dosage form formulated for oral, vaginal, intravenous, transdermal, subcutaneous, intraperitoneal, or intramuscular administration.
6. A method comprising:
contacting an endometriotic lesion cell with an autophagic inhibitor in an amount effective to treating the edometriotic lesion.
7. The method of claim 6 , wherein contacting an endometriotic lesion cell with an effective amount of an autophagic inhibitor prevents recurrance of an endometriotic lesion cell.
8. The method of claim 6 , wherein the autophagic inhibitor is selected from the group consisting of chloriquine, Lys05, hydroxychloriquine, pharmaceutically acceptable salts thereof, ATG5 siRNA, ATG7 siRNA, or combinations thereof.
9. The method of claim 6 , wherein the autophagic inhibitor is hydroxychloriquine.
10. The method of claim 6 , wherein the effective amount ranges from about 1 mg/kg to about 200 mg/kg.
11. The method of claim 6 , wherein the endometriotic lesion cell has greater expression as compared to a control cell of at least one autophagic marker selected from the group consisting of ATG7, ATG5, and hVps34.